From cancer to autoimmune disorders to inflammation and immunology, small molecules form the backbone of most innovative treatments across a spectrum of diseases. Their versatility and adaptability, as well as relative ease of manufacturing, make them invaluable assets in the quest for new therapies.
At InnoCore, we leverage this flexibility by integrating small molecules into long-acting injectable (LAI) systems using our proprietary SynBiosys® drug delivery platform. These platforms enable finely tuned, sustained release, from days up to over a year, offering patients predictable pharmacokinetics and improved treatment adherence.
Whether injected locally or subcutaneously, SynBiosys® offers sustained and tunable drug delivery for small molecules for up to 18 months. Our technology excels in controlled diffusion, high drug loading, and stability for both local and systemic delivery.
Examples of small molecules
Small molecules are distinct in their therapeutic versatility, able to interact with cell receptors, enzymes, and intracellular machinery due to their size and bioavailability. Their adaptability, chemical diversity, and cost-effective synthesis make them critical in areas like metabolic disease, CNS disorders, and oncology.
InnoCore’s SynBiosys® drug delivery platform offers customizable sustained-release formulations using proprietary biodegradable polymers. The release rate can be precisely tuned from weeks to over 1 year by altering the polymeric composition. Our technology ensures sustained therapeutic delivery with minimal burst. We can offer high drug loading , , scalability, and protection from degradation during processing, formulation and release.
Whether delivered via microspheres, implants or in situ forming depots , InnoCore’s system enhances the flexibility in drug design and delivery. This adaptability enables localized and systemic delivery strategies tailored to therapeutic goals.
InnoCore’s polymers are built from well-characterized, clinically validated monomers, simplifying regulatory approval processes. Our technology supports formulations that are compatible with GLP and cGMP manufacturing, enabling seamless transition from preclinical development to clinical production.
Small molecules remain foundational to modern therapeutics, yet their clinical potential hinges on effective delivery strategies. InnoCore’s SynBiosys® drug delivery platform harnesses our deep formulation expertise and polymer innovation to transform small molecules into novel long-acting, patient-friendly therapies. With precise sustained release control, high stability, and robust development support, InnoCore empowers drug developers to elevate small molecule programs into differentiated, high-value treatments.
"*" indicates required fields